Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Lithium Dosing Study (LiDS)

10 novembre 2026 aggiornato da: Olivia I.Okereke, MD, Massachusetts General Hospital

Dosing Study of Lithium Orotate for Safety, Tolerability, and Feasibility for Early Stages of Alzheimer's Disease and Related Dementias

LiDS is a dosing study to evaluate the safety, tolerability, and feasibility of daily oral Lithium Orotate (LiO) in aging adults at increased risk for progression of cognitive problems, including Alzheimer's disease and related dementias.

Panoramica dello studio

Descrizione dettagliata

Lithium orotate (LiO), a compound combining lithium with orotic acid, has shown remarkable neuroprotective effects in preclinical studies by our group - reducing amyloid plaques, lowering brain inflammation, and improving memory. Early human studies suggest that low doses may be safe and potentially beneficial for brain function. Given its affordability, accessibility, and considerably lower side effect profile compared to other lithium-based compounds, LiO warrants further human investigation. However, more information must first be obtained regarding the effects of LiO on the human body, focused on the safety and tolerability of LiO supplementation at various amounts. We propose a 12-week dose-ranging study to evaluate the safety, tolerability, and feasibility of daily oral LiO at different doses of elemental lithium among aging adults across a cognitive spectrum and at risk for progressing to worsening cognitive function, including those with subjective cognitive complaints, mild objective cognitive impairment, or moderate objective cognitive impairment. This represents the most relevant study population in whom to evaluate potential effects of LiO on the human body.

Specific Aims and Objectives

The primary objectives for this dose-ranging trial are to assess:

Safety: Side effects will be tracked via serial REDCap web-based surveys. Blood samples will be collected at baseline and prior to the final study visit (between 8 and 12 weeks during randomized treatment) with thyroid, liver, and kidney function monitoring.

Tolerability: Participants' adherence to assigned study pills and study withdrawal rates will be monitored through regular web-based surveys.

Feasibility: Feasibility will be determined by the successful completion of study procedures, including recruitment and enrollment rates; compliance rates with web-based surveys; participation rates in blood sample collections; change in lithium levels in active vs. placebo groups.

Secondary objectives will involve use of: 1) survey measures of mood, thinking, or functioning, as these represent important additional safety variables (i.e., change in mood or suicidal ideation) and/or common nuisance side effects (i.e., changes in subjective cognition and everyday functioning) that may account for a large share of differences in tolerability of lithium; 2) additional blood biomarkers designed to further capture the effects of the supplement on the human body.

Tipo di studio

Interventistico

Iscrizione (Stimato)

250

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

60 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Age 60 years or older at study entry Self-reported ability to read and understand English. As all study surveys have been validated in English, we will limit participation to potential subjects able to read English.

Able to provide informed consent

Must meet criteria for one of the three following cognitive statuses:

Cognitively normal/unimpaired, (TICS-41 score ≥34 with presence of subjective cognitive concerns and without significant hearing impairment

For those without hearing impairment, TICS-41 score 23 to <34 (mild objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of MCI

For those without hearing impairment, TICS-41 score >15 to <23 (moderate objective cognitive impairment); or for those with hearing impairment, self-reported clinician diagnosis of mild-stage AD dementia

Must be able and willing to adhere to study procedures

Participants with moderate objective impairment or clinician diagnosis of AD dementia must have a study partner willing to participate in the study with them.

Exclusion Criteria:

Lithium-specific exclusions

History of lithium toxicity, intolerance or hypersensitivity

Use of any lithium formulation in the last six months

History of diagnosed kidney disorders (e.g., chronic kidney disease, dialysis or renal transplant, acute kidney injury within past 6 months)

Unstable thyroid disorders (e.g., medication change in the last 90 days) or history of thyroid surgery, radioactive iodine treatment or active thyroiditis in the last 90 days

Unwilling to forego use of any non-study lithium formulation during the trial

Self-reported major psychiatric and neurological disorders

Bipolar disorder, schizophrenia, or unstable major depression (e.g., recent hospitalization, medication change in the last 90 days).

To optimize participant safety and to ensure that individuals with any degree of suicidal ideation at baseline are not included in the study, the presence of any suicidal ideation at screening will be defined as a score of >0 on PHQ-9 Item 9 or as spontaneously reported during screening. The PHQ-9 will also be administered at 6- and 12-week follow-up time points as a safety monitoring measure. A score of 1 or greater on PHQ-9 Item 9, or spontaneous report of current suicidal ideation at any point during the study, will trigger the suicidality and psychiatric safety procedures detailed under 'Monitoring and Quality Assurance'.

Parkinson disease or other non-AD neurodegenerative disorders (e.g., Huntington's disease)

Self-reported medical conditions

Diagnosis of cardiovascular disease or major cardiovascular procedures in the last 6 months (e.g., cardiac conduction abnormalities, heart attack, stroke, transient ischemic attack, angina pectoris, coronary-artery bypass grafting, percutaneous coronary intervention, cardioversion or ablation)

Diagnosis or treatment of cancer (except non-melanoma skin cancer) in the last 6 months

Concurrent use of anti-amyloid therapies (e.g., Donanemab, Lecanemab)

History of liver disease

Other exclusions

Lab values within the abnormal range (adjusted for age and sex where relevant) for renal function, reflex thyroid tests, and liver function

TICS-41 score ≤15

Score of >50% likelihood of significant hearing impairment according to the Hearing Handicap Inventory-Screening Version (HHIE-S)

Any other serious illness or condition that, in the opinion of the investigators, would preclude safe participation or completion of the study procedures

Concurrent participant in an ongoing clinical trial involving taking a study drug or supplement

Those who report "severe" for items 21-29 on the LiSERS questionnaire

UBACC (the University of California, San Diego Brief Assessment of Capacity to Consent) < 11 indicating inability to provide informed consent. The clinical research coordinator will conduct a comprehension check of the consent form using the UBACC, which will require a perfect score of 11 out of 11 points to indicate capacity to provide informed consent. Prospective participants will be allowed two tries of the UBACC to achieve a score of 11.

Those with hearing impairment who do not report a clinician diagnosis of MCI or AD dementia given concerns for lack of awareness of objective memory decline which could lead to incorrect categorization without use of the TICS-41

Must reside in the states of Connecticut, Rhode Island, Massachusetts, Maine, New Hampshire, or Vermont and be able to have blood draws completed at a New England Quest location in those states.

Failure to complete the baseline blood collection.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo

Placebo pill taken daily for the 12 week study participation period. Placebo pills are in packaging identical to the LiO groups.

Placebo pill for the Lithium orotate.

Comparatore attivo: 0.5 mg/day

0.5 mg/day of LiO pills for the 12 week study participation period.

Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.

Comparatore attivo: 1.0 mg/day

1.0 mg/day of LiO pills for the 12 week study participation period.

Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.

Comparatore attivo: 2.5 mg/day

2.5 mg/day of LiO pills for the 12 week study participation period.

Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.

Comparatore attivo: 5.0 mg/day

5.0 mg/day of LiO pills for the 12 week study participation period.

Lithium orotate dietary supplement pills in the doses of 0.5, 1.0, 2.5, or 5.0 mg/day.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety Monitoring
Lasso di tempo: 12 weeks

Blood samples will be collected at baseline and at a second timepoint prior to the end of the intervention (between 8 and 12 weeks during randomized treatment) for thyroid, liver, and kidney function monitoring. The safety measure is number (%) of participants with abnormal safety events. The safety measures monitored will be Thyroid Stimulating Hormone (TSH with reflex) above or below normal range, Liver Function Tests (LFTs) above normal range, and estimated glomerular filtration rate (EGFR) below 60. A safety event will be considered as an abnormality on any one of these indicators.

12 weeks
Tolerability: Study Withdrawal
Lasso di tempo: 12 weeks

Tolerability: Counts and percentages of participants who withdraw from study participation.

12 weeks
Tolerability: Adherence to Study Pills
Lasso di tempo: 12 weeks

Tolerability: Participants' adherence to assigned study pills will be monitored through regular web-based surveys and summarized descriptively; proportion of participants achieving predefined adherence thresholds (e.g. taking >=75% of study supplements) will also be reported.

12 weeks
Recruitment
Lasso di tempo: 6 months

Recruitment number (count) and percent of planned enrollment.

6 months
Compliance: Questionnaire Data
Lasso di tempo: 12 weeks

Study compliance as completion rates (counts and percentages) of the web-based questionnaires.

12 weeks
Compliance: Blood Collection
Lasso di tempo: 12 weeks

Counts and percentages of individuals completing the first and final blood collections

12 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Everyday Cognition(ECoG)
Lasso di tempo: 12 weeks

Survey measure of memory or thinking, using the ECOG, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in subjective cognition) that may be relevant to tolerability of lithium. ECOG items are scored 1-4 points, with worse cognition signified by higher scores. The total score range is 12-48 points.

12 weeks
Older Americans Resources and Services-Instrumental Activities of Daily Living (OARS-IADL)
Lasso di tempo: 12 weeks

Survey measure of functioning, using the OARS-IADL, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in everyday functioning related to cognition) that may be relevant to tolerability of lithium. A subset of questions from the IADL component of the OARS will be administered via survey. Each item is score 0, 1, or 2, or not applicable/not answered, where higher scores represent greater functional independence and lower scores represents lower functional independence. The total range is 0-12 points.

12 weeks
Functional Activities Questionnaire (FAQ)
Lasso di tempo: 12 weeks

Survey measure of functioning, using the FAQ, as this represents an important safety variable and/or common area of nuisance side effects (i.e., changes in everyday functioning related to cognition) that may be relevant to tolerability of lithium. The FAQ features 10 items, each with values between 0 to 3 (or not applicable). The total score range is 0-30 points, with higher scores indicating higher functional dependency or impairment.

12 weeks
Patient Health Questionnaire-9 (PHQ-9)
Lasso di tempo: 12 weeks

Survey measure of functioning, using the PHQ-9, as this represents an important safety variable and/or common area of nuisance side effects (changes in mood and/or suicidality) that may be relevant to tolerability of lithium. The PHQ-9 features 9 items, each with values between 0 to 3 (or not applicable). The total score range is 0-27 points, with higher scores indicating higher levels of depressive symptoms.

12 weeks
Lithium Side Effects Rating Scale (LiSERS)
Lasso di tempo: 12 weeks

The LiSERS survey is used to measure absence, presence, and/or degree of severity (where applicable/present) to common or known potential side effects of lithium. The LiSERS features 30 items, for which respondents indicate yes or no; if yes, respondents further indicate degree of severity.

12 weeks
Additional Blood Biomarkers
Lasso di tempo: 12 weeks

Additional blood biomarkers (Lithium level, inflammatory markers, and ADRD biology markers, specifically pTau217) designed to further capture the effects of the supplement on the human body. These continuous measures of blood biomarkers will be reflected as levels or concentrations of the respective biomarkers.

12 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Olivia I Okereke, PhD, Massachusetts General Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

16 novembre 2026

Completamento primario (Stimato)

30 giugno 2027

Completamento dello studio (Stimato)

1 novembre 2027

Date di iscrizione allo studio

Primo inviato

25 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Blinded study design; study group data will be analyzed in the aggregate. No Individual Participant Data will be shared.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi